Patents Issued in September 30, 2014
-
Patent number: 8846596Abstract: Liquid cleaning compositions are described herein that include a metal bleach catalyst which is a complex of a transition-metal and a macrocyclic ligand, the ligand having a calculated Octanol/Water Partition Coefficient value of from about ?1.50 to about ?0.10, a formulation enabling fraction comprising at least one formulation enabling ingredient, the formulation enabling fraction having a Hydrophilic Index of from about 4.0 to about 10.0, and a formulation deactivating fraction comprising at least one formulation deactivating ingredient that has a calculated Octanol/Water Partition Coefficient value of from about ?3.5 to about ?0.10.Type: GrantFiled: February 16, 2012Date of Patent: September 30, 2014Assignee: The Procter & Gamble CompanyInventors: Robert Richard Dykstra, Mario Elmen Tremblay, Xiaoru Jenny Wang, James Lee Danziger, Daniel Dale Ditullio, Jr., Consuelo Kong, Ismael Cotte-Rodriguez
-
Patent number: 8846597Abstract: Methodologies and equipment for using a hypochlorite solution to remove menstrual fluid, underarm perspiration or other hard-to-remove stains from soft fabric articles with reduced damage to the fabric articles when compared with popular chlorine bleaches. The soft fabric articles preferably are in white, although the present invention can also be applied to articles in other colors. In one embodiment, the weight concentration ratio of the alkali metal hydroxide over the hypochlorite salt in the hypochlorite solution is no less than 1:12.5. The hypochlorite solution may contain at least 0.2% by weight of sodium hydroxide and/or have a pH of at least 11.8.Type: GrantFiled: January 7, 2013Date of Patent: September 30, 2014Assignee: LH Taylor AssociatesInventor: Lawnie Henderson Taylor
-
Patent number: 8846598Abstract: The present invention relates to a composition comprising: (i) a bacterial alkaline enzyme exhibiting endo-beta-1,4-glucanase activity (E.C. 3.2.1.4); and (ii) a bleach catalyst that is capable of accepting an oxygen atom from a peroxyacid and transferring the oxygen atom to an oxidizeable substrate.Type: GrantFiled: July 9, 2007Date of Patent: September 30, 2014Assignee: The Procter & Gamble CompanyInventors: Neil Joseph Lant, Gregory Scot Miracle, Philip Frank Souter
-
Patent number: 8846599Abstract: Branched polyesters with sulfonate groups obtainable by the reaction of the components A, B, optionally C and optionally D to give branched polyesters, where the component A is selected from the group of ?,?-olefinically unsaturated dicarboxylic acids, and the component B is selected from the group of tri- or higher-functional alcohols, the optional component C is selected from the group of difunctional alcohols or of difunctional carboxylic acids without ?,?-olefinically unsaturated bonds, the optional component D is selected from fatty acids or fatty alcohols, and the subsequent reaction of the resulting branched polyesters with hydrogen sulfite, where the molar amount of hydrogen sulfite is at most 95 mol %, based on the amount of ?,?-olefinically unsaturated dicarboxylic acid.Type: GrantFiled: June 13, 2012Date of Patent: September 30, 2014Assignee: BASF SEInventors: Monika Haberecht, Frank Rittig, Bernd Bruchmann, Claudia Esper, Roland Ettl, Karl Kolter
-
Patent number: 8846600Abstract: Disclosed are carboxamide compounds as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure in which R1, R2, R3, R4, T, p, q, w and x are as described herein. In certain embodiments, a compound disclosed herein activates the AMPK pathway, and can be used to treat metabolism-related disorders and conditions.Type: GrantFiled: December 27, 2012Date of Patent: September 30, 2014Assignee: Rigel Pharmaceuticals, Inc.Inventors: Ihab S. Darwish, Hui Hong, Rajinder Singh, Xiang Xu
-
Patent number: 8846601Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and z are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.Type: GrantFiled: December 6, 2011Date of Patent: September 30, 2014Assignee: Palatin Technologies, Inc.Inventors: Yi-qun Shi, Shubh D. Sharma, John H. Dodd, Wei Yang, Xin Chen
-
Patent number: 8846602Abstract: The invention relates to a method for producing injectable medicament preparations containing a therapeutically and/or diagnostically effective substance which is comprised of an active agent, of a spacer molecule and of at least one protein-binding molecule. After being brought into contact with the body, said therapeutically and/or diagnostically effective substance covalently bonds to the body fluid constituents or tissue constituents via the protein-binding molecule, thus providing a form of transport of the active agent that an be hydrolytically or enzymatically cleaved, according to pH, in the body while releasing the active agent.Type: GrantFiled: March 7, 2012Date of Patent: September 30, 2014Assignee: KTB Tumorforschungs GmbHInventor: Felix Kratz
-
Patent number: 8846603Abstract: The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.Type: GrantFiled: March 11, 2011Date of Patent: September 30, 2014Assignee: Synageva Biopharma Corp.Inventors: Anthony Quinn, Alex J. Harvey, Zhinan Xia
-
Patent number: 8846604Abstract: The invention provides lipid compositions comprising phospholipids having a high docosahexaenoic acid (DHA) content, which compositions are preferably extracted from natural sources. The lipid compositions are excellent sources of highly bioavailable DHA and they can be used in oral delivery vehicles, dietary supplements, functional foods, and the like.Type: GrantFiled: August 31, 2012Date of Patent: September 30, 2014Assignee: Artic Nutrition ASInventors: Hogne Hallaraker, Jan Remmereit, Alvin Berger
-
Patent number: 8846605Abstract: This invention relates to a topical gel drug product preparation containing a composition comprising an isolated polypeptide having a carboxy-terminal amino acid sequence of an alpha connexin (ACT peptide), peptide stabilizers, excipients, buffering agents, and the like. A formulation and preparation steps are disclosed for the manufacturing of a stable, elegant, and pourable topical gel. The resulting formulation possesses long term stability suitable for aesthetic as well as therapeutic applications including the prevention of scaring and accelerated healing of wounds. Methods for treatment of chronic wounds, including chronic ulcers, are also provided.Type: GrantFiled: March 15, 2013Date of Patent: September 30, 2014Assignee: Firstring Research, Inc.Inventor: Gautam Ghatnekar
-
Patent number: 8846606Abstract: Provided herein are methods and compositions for treating septic hypotension. More specifically, the methods may comprise, administering one alpha-2 agonist or other sympatholytic and at least one vasopressor.Type: GrantFiled: June 24, 2011Date of Patent: September 30, 2014Inventor: Luc Quintin
-
Patent number: 8846607Abstract: Formulations have been developed to treat or reduce the spread of respiratory infections, especially chronic or drug resistant infections, particularly tuberculosis (TB), severe acute respiratory syndrome (SARS), meningococcal meningitis, Respiratory syncytial virus (RSV), influenza, and small pox. Formulations include a drug or vaccine in the form of a microparticle, nanoparticle, or aggregate of nanoparticles, and, optionally, a carrier, which can be delivered by inhalation. Giving the drugs via an inhaler sidesteps the problems associated with oral or injectable drugs by bypassing the stomach and liver, and delivering the medication directly into the lungs. In one embodiment, the particle containing the agent is a large porous aerosol particle (LPPs). In another embodiment, the particles are nanoparticles, which can be administered as porous nanoparticle aggregates with micron diameters that disperse into nanoparticles following administration.Type: GrantFiled: October 19, 2005Date of Patent: September 30, 2014Assignee: President and Fellows of Harvard CollegeInventors: David A. Edwards, Jennifer Fiegel, Jean Sung
-
Patent number: 8846608Abstract: The present invention relates to new peptides and to use thereof, in particular for treatment and/or prevention of infections, inflammations, pain, wounds, scar and/or tumors.Type: GrantFiled: January 25, 2012Date of Patent: September 30, 2014Assignee: Pergamum ABInventors: Margit Mahlapuu, Camilla Björn, Veronika Sjöstrand, Björn Walse, Bo Svenson
-
Patent number: 8846609Abstract: The present invention relates to methods for preventing or treating Human Immunodeficiency Virus (HIV) infection, inflammatory conditions, and graft-versus-host-disease (GVHD) in a subject. Therapeutic compositions of the present invention comprise Leukocidin E (LukE) and/or D proteins or polypeptides. The invention further relates to methods of treating Staphylococcus aureus infection by administering a composition comprising a CCR5 antagonist or any molecule that blocks LukE/D interaction with CCR5+ cells in an amount effective to treat the S. aureus infection in the subject.Type: GrantFiled: June 19, 2012Date of Patent: September 30, 2014Assignee: New York UniversityInventors: Victor J. Torres, Derya Unutmaz, Francis Alonzo, III
-
Patent number: 8846610Abstract: The present invention relates to crystalline and crystal-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention also relates to pharmaceutical compositions comprising the purified form of the lipopeptide and methods of using these compositions.Type: GrantFiled: July 31, 2013Date of Patent: September 30, 2014Assignee: Cubist Pharmaceuticals, Inc.Inventors: Dennis Keith, Jan-Ji Lai, Chandrika Govardhan, Nazer Khalaf
-
Patent number: 8846611Abstract: Disclosed herein is a skin condition-improving composition for topical application to the skin, comprising human growth hormone as an active ingredient, and a method for improving skin conditions using the same. The disclosed composition exhibits various skin conditioning effects, such as acne treatment, wrinkle improvement, dark spot removal, skin elasticity improvement, hair growth stimulation, skin aging prevention, skin moisturization and the proliferation of skin epidermal stem cells.Type: GrantFiled: April 12, 2006Date of Patent: September 30, 2014Assignee: Regeron, Inc.Inventors: Dahl Kyun Oh, Sang Jung Baik, Kyung Young Lee
-
Patent number: 8846612Abstract: The use of a protein source comprising bovine casein proteins for the preparation of a nutrional composition for administration to an infant, young child or adult during or after a period of catch-up growth or weight recovery, following a period of growth restriction or weight lost, so as improve growth at early age and/or to reduce the risk of development of insulin resistance and/or Type 2 diabetes later in the life of the infant, young child or adult.Type: GrantFiled: March 26, 2010Date of Patent: September 30, 2014Assignee: Nestec S.A.Inventors: Olivier Aprikian, Florence Blancher, Catherine Mace, Yassaman Shahkhalili
-
Patent number: 8846613Abstract: The invention relates to a pharmaceutical composition comprising 1.a and/or 1.b according to claim 1 in combination with at least one second therapeutic agent 2 which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.Type: GrantFiled: October 8, 2013Date of Patent: September 30, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Bradford S. Hamilton, Thomas Rauch, Manami Tsutsumi
-
Patent number: 8846614Abstract: A process for the production of pramlintide, a 37-mer peptide, is provided. The synthesis provides a high yield synthesis of the peptide in relatively pure form. Further purification can be achieved by preparative HPLC.Type: GrantFiled: August 22, 2012Date of Patent: September 30, 2014Assignee: USV LimitedInventors: Nikhil Umesh Mohe, Praful Shamrao Chavre, Bharti Prabhakarrao Deshmukh, Chandrakesan Muralidharan, Lester John Lobo, Digamber Shripati Pawar, Divya Lal Saksena
-
Patent number: 8846615Abstract: The present invention relates to novel Motoneuronotrophic Factors (MNTF) peptides and analogs thereof, including compositions capable of promoting the growth and viability of neurons. MNTF peptides between two and six amino acids in length are provided, as well as analogs of these MNTF peptides that are modified by covalent attachment to another moiety. Other embodiments are described herein.Type: GrantFiled: February 23, 2009Date of Patent: September 30, 2014Assignee: Genervon Biopharmaceuticals, LLCInventors: Pui-Yuk Dorothy Ko, Mark S. Kindy
-
Patent number: 8846616Abstract: A method is presented for treating an inflammatory skin disorder in a human comprising: topically applying to the skin a composition comprising alpha-melanocyte stimulating hormone (?MSH) or an ?MSH analog in an amount effective to reduce skin inflammation in the human.Type: GrantFiled: November 9, 2010Date of Patent: September 30, 2014Assignees: Florida Agricultural and Mechanical University, The Board of Trustees at the University of ArkansasInventors: Mandip Singh Sachdeva, Cheryl Armstrong, Melissa A. Brown
-
Patent number: 8846617Abstract: The present invention relates to the use of compounds selected from the group consisting of Lys-(D)Pro-Thr, N-acyl Lys-(D)Pro-Thr, C-amide Lys-(D)Pro-Thr, and C-esters of Lys-(D)Pro-Thr; or a pharmaceutically acceptable salt of said compound fort he treatment of inflammatory disorders. The invention also relates to the use of ?MSH for inducing tolerance.Type: GrantFiled: July 16, 2011Date of Patent: September 30, 2014Inventor: Thomas Luger
-
Patent number: 8846618Abstract: Pharmaceutical formulations of GLP-1 compounds and methods for preparation thereof.Type: GrantFiled: May 24, 2010Date of Patent: September 30, 2014Assignee: Novo Nordisk A/SInventors: James M. Flink, Silke Møller Larsen, Simon Bjerregaard Jensen, Dorthe Kot Engelund
-
Patent number: 8846619Abstract: This invention provides heme-containing peptides capable of binding molecular oxygen at room temperature. These compounds may be useful in the absorption of molecular oxygen from molecular oxygen-containing atmospheres. Also included in the invention are methods for treating an oxygen transport deficiency in a mammal.Type: GrantFiled: March 4, 2010Date of Patent: September 30, 2014Assignee: The Trustees of the University of PennsylvaniaInventor: P. Leslie Dutton
-
Patent number: 8846620Abstract: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation enhancer is orally administered to a subject in a manner sufficient to enhance blood coagulation in the subject. Compositions and kits for practicing methods of the invention are also described.Type: GrantFiled: July 18, 2012Date of Patent: September 30, 2014Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Peter Turecek, Susanne Vejda
-
Patent number: 8846621Abstract: Pharmaceutical compositions and methods for treating diseases associated with angiogenesis and inflammation. The invention relates to a pharmaceutical composition that includes a therapeutically effective amount of sCD26 and/or a biologically active derivative thereof and a pharmaceutically acceptable carrier. The composition may further include a therapeutically effective amount of sFlt-1 and/or a biologically active derivative thereof. Additionally, the invention relates to methods for treating a disease associated with and/or progresses by an inflammatory cytokine-associated inflammation and/or VEGF-associated angiogenesis.Type: GrantFiled: December 1, 2009Date of Patent: September 30, 2014Inventor: Chiwen Chang
-
Patent number: 8846622Abstract: Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the sphenopalatine ganglion. Exemplary delivery is carried out by way of injection.Type: GrantFiled: August 15, 2013Date of Patent: September 30, 2014Assignee: Allergan, Inc.Inventor: Andrew M. Blumenfeld
-
Patent number: 8846623Abstract: Cancer-targeting peptides having a PX1LX2 motif, in which X1 is His or an amino acid residue with a hydrophobic side chain and X2 is Pro, Phe, or Trp. Also disclosed herein are conjugates containing the cancer-targeting peptides and uses thereof in cancer treatment and diagnosis.Type: GrantFiled: October 25, 2011Date of Patent: September 30, 2014Assignee: Academia SinicaInventors: John Yu, Alice L. Yu, H. C. Wu, Sheng-Hung Wang, I-Ju Chen
-
Patent number: 8846624Abstract: In an embodiment, a number of synthetic protein triblock copolymers are provided comprising first and second end hydrophobic blocks separated by a central hydrophilic block. In particular, the synthetic proteins are elastin-mimetic proteins having improved mechanical characteristics and related methods of making the proteins with the capability of providing precise control over the mechanical properties. Provided are proteins used in a number of medical devices such as artificial blood vessels, shunts, stents or as embolic agents in situations where it is desired to stop or reduce blood flow or pressure in a localized region.Type: GrantFiled: September 11, 2007Date of Patent: September 30, 2014Assignee: Emory UniversityInventors: Elliot L. Chaikof, Vincent P. Conticello
-
Patent number: 8846625Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.Type: GrantFiled: March 11, 2013Date of Patent: September 30, 2014Assignee: 1149336 Ontario Inc.Inventors: Daniel J Drucker, Anna E. Crivici, Martin Sumner-Smith
-
Patent number: 8846626Abstract: A drug composition for treating chronic liver diseases, consists of: Astragalus Astragalosides and Glycyrrhiza Acid by weight ratio of 3˜6:1. By testing and validating with classic animal model, the results confirmed that the drug composition of the present invention can significantly reduce the collagen content of rat liver, and reduce liver fibrosis and liver injury, wherein the effect is better than the effect of each component alone. The drug composition of the two components or ingredients can improve the anti-hepatic fibrosis, effectively prevent liver fibrosis and promote the development of liver fibrosis reversal, and thus can be used for the treatment and prevention of various chronic hepatitis, liver fibrosis, cirrhosis and other illnesses.Type: GrantFiled: August 26, 2011Date of Patent: September 30, 2014Assignee: Shuguang Hospital Affiliated with Shanghai University of Traditional Chinese MedicineInventor: Ping Liu
-
Patent number: 8846627Abstract: A method for treatment of malaria including administering to a patient in need thereof a flavonoid glycoside compound.Type: GrantFiled: April 23, 2012Date of Patent: September 30, 2014Assignees: The Second Military Medical University, East China University of Science and TechnologyInventors: Weidong Zhang, Jin Huang, Lei Shan, Honglin Li, Liyan Wang, Shoude Zhang, Weiqiang Lu, Juan Su, Tong Chen
-
Patent number: 8846628Abstract: The present disclosure provides pharmaceutical compositions comprising cytidine analogs, for example, 5-azacytidine or decitabine, for oral administration, wherein the compositions release the cytidine analog, for example, 5-azacytidine or decitabine, substantially in the stomach. Also provided are methods of treating diseases and disorders using the oral formulations provided herein.Type: GrantFiled: May 14, 2009Date of Patent: September 30, 2014Assignee: Celgene CorporationInventors: Jeffrey B. Etter, Mei Lai, Jay Thomas Backstrom
-
Patent number: 8846629Abstract: A method for treatment and amelioration of breast, cervical, ovarian, endometrial, squamous cells, prostate cancer and melanoma in a patient comprising targeting Id-1 or Id-2 gene expression with a delivery vehicle comprising a product which modulates Id-1 or Id-2 expression.Type: GrantFiled: December 2, 2008Date of Patent: September 30, 2014Assignees: The Regents of the University of California, California Pacific Medical Center Research InstituteInventors: Pierre-Yves Desprez, Judith Campisi
-
Patent number: 8846630Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.Type: GrantFiled: November 1, 2010Date of Patent: September 30, 2014Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Misun Won, Kyung-Sook Chung, Young Joo Kim, Hye Kyung Hong, Young Il Yeom, Chae Ok Yun, Yu-Kyoung Oh, Kyung Bin Song, Hee Gu Lee, Young Ho Kim, Moon Hee Kim, Kyeong-Eun Jung, Seok Hoon Song
-
Patent number: 8846631Abstract: Provided herein are compositions comprising oligomeric compounds. In certain embodiments, the oligomeric compounds are useful as miRNA mimics. The oligomeric compounds may mimic the activity of miR-34. Also provided herein are methods for the treatment of cancer.Type: GrantFiled: January 14, 2011Date of Patent: September 30, 2014Assignee: Regulus Therapeutics Inc.Inventors: Eric G. Marcusson, Balkrishen Bhat, Peter Linsley, Akin Akinc
-
Patent number: 8846632Abstract: Compositions and methods effective for modulating Hepatitis C viral infection are provided.Type: GrantFiled: September 4, 2012Date of Patent: September 30, 2014Assignee: The Children's Hospital of PhiladelphiaInventor: Linda B. Couto
-
Patent number: 8846633Abstract: The present invention provides a method for inhibiting cancer stem cell like properties and chemoradioresistant properties of cancer or tumor cells comprising delivering miR145 to the cancer or tumor cells, particularly brain tumor and head and neck cancer cells. The invention further provides a pharmaceutical composition comprising miR145 and a method for treating brain tumor and/or head and neck cancer comprising administration of miR145 to a subject in need thereof.Type: GrantFiled: November 7, 2012Date of Patent: September 30, 2014Assignee: Taipei Veterans General HospitalInventors: Shih-Hwa Chiou, Han-Shui Hsu, Jong-Yuh Cherng
-
Patent number: 8846635Abstract: The present application provides methods and compositions for inducing hepatocyte proliferation and liver regeneration, the latter being mainly dependent on hepatocyte proliferation even if all the other cell types divide to reconstitute the organ specific-lobular-architecture. The methods and compositions provided herein make use of an A3AR agonist. A preferred A3AR agonist disclosed herein is Cl-IB-MECA.Type: GrantFiled: October 22, 2008Date of Patent: September 30, 2014Assignee: Can-Fite Biopharma Ltd.Inventors: Pnina Fishman, Shira Cohen
-
Patent number: 8846636Abstract: The disclosure provides nucleotide analogues that comprise tetrahydrofuranyl or tetrahydrothienyl moieties with quaternary centers at the 3? position, the pharmaceutical formulations comprising the analogues, and methods of using the analogues and formulations for treating, preventing, and/or inhibiting diseases or conditions associated with cancers and viruses.Type: GrantFiled: March 18, 2009Date of Patent: September 30, 2014Assignee: LCB Pharma Inc.Inventor: Yvan Guindon
-
Patent number: 8846637Abstract: Provided herein are 2?-amino and 2?-thio bicyclic nucleosides and oligomenc compounds prepared therefrom. The novel bicyclic nucleosides provided herein are expected to be useful for enhancing one or more properties of the oligomeric compounds they are incorporated into such as nuclease resistance.Type: GrantFiled: June 2, 2011Date of Patent: September 30, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Thazha P. Prakash, Eric E. Swayze
-
Patent number: 8846638Abstract: The present invention provides nucleoside phosphoramidate compounds of Formula I, where R1, R2a, R2b, R3, R4, R5a, R5b, R6, R7, R8a, R8b, M and W are as defined herein. The invention further includes pharmaceutical compositions comprising a compound of Formula I, methods of use of these compounds for treating a viral infection, and methods of producing these compounds.Type: GrantFiled: May 17, 2013Date of Patent: September 30, 2014Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yat Sun Or, Jun Ma, Guoqiang Wang
-
Patent number: 8846639Abstract: In certain embodiments, the present invention provides oligomeric compounds having favorable toxicity profiles and therapeutic indexes. Compounds of the present invention comprise bicyclic nucleosides. Certain such bicyclic nucleosides are pyrimidines that do not include a methyl group at the 5-carbon. Oligomeric compounds comprising such nucleosides are less toxic than compounds comprising bicyclic nucleosides that do include a methyl group at the 5-carbon. In certain embodiments, the present invention provides methods of preparing and using such compounds.Type: GrantFiled: April 3, 2009Date of Patent: September 30, 2014Assignee: Isis Pharmaceutical, Inc.Inventors: Eric E. Swayze, Andrew M. Siwkowski
-
Patent number: 8846640Abstract: Biomaterials obtainable by mixing the autocrosslinked derivative of hyaluronic acid (ACP) with the derivative (HBC) of hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether (BDDE) in the weight ratio of between 10:90 and 90:10 as novel fillers.Type: GrantFiled: August 25, 2010Date of Patent: September 30, 2014Assignee: Fidia Farmaceutici S.p.A.Inventors: Matteo D'este, Davide Renier
-
Patent number: 8846641Abstract: The present invention relates to viscosity stabilized ophthalmic formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a diol alcohol such as sorbitol and, optionally, a pharmaceutically acceptable divalent cation salt such as magnesium chloride.Type: GrantFiled: May 13, 2013Date of Patent: September 30, 2014Assignee: Alcon Research, Ltd.Inventors: Howard Allen Ketelson, James W. Davis, David L. Meadows
-
Patent number: 8846642Abstract: A nutritional composition for administration to an infant which composition comprises, on a dry matter basis, from 2.5 to 15.0 wt % of an oligosaccharide mixture consisting of N-acetylated oligosaccharide(s), galacto-oligasaccharide(s) and sialylated oligosaccharide(s) with the proviso that the composition comprises at least 0.02 wt % of an N-acetylated oligosaccharide, at least 2.0 wt % of a galacto-oligosaccharide and at least 0.04 wt % of a sialylated oligosaccharide and that the N-acetylated oligosaccharide(s) comprise 0.5 to 4.0% of the oligosaccharide mixture, the galacto-oligosaccharide(s) comprise 92.0 to 98.5% of the oligosaccharide mixture and the sialylated oligosacchardide(s) comprise 1.0 to 4.0% of the oligosaccharide mixture. The composition is useful for administration to an infant in the first six months of life to reduce the risk of obesity later in life.Type: GrantFiled: April 10, 2013Date of Patent: September 30, 2014Assignee: Nestec S.A.Inventors: Marie-Claire Fichot, Norbert Sprenger, Francois-Pierre Martin, Sunil Kochhar, Serge Rezzi
-
Patent number: 8846643Abstract: There are provided, inter alia, acyclic nucleoside phosphonate compounds having reduced toxicity and enhanced antiviral activity, and pharmaceutically accepted salts and solvates thereof. There are also provided methods of using the disclosed compounds for inhibiting viral RNA-dependent RNA polymerase, inhibiting viral reverse transcriptase, inhibiting replication of virus, including hepatitis C virus or a human retrovirus, and treating a subject infected with a virus, including hepatitis C virus or a human retrovirus.Type: GrantFiled: October 11, 2012Date of Patent: September 30, 2014Assignee: The Regents of the University of CaliforniaInventors: Karl Y. Hostetler, James R. Beadle, Nadejda Valiaeva
-
Patent number: 8846644Abstract: A phosphate-containing nanoparticle delivery vehicle includes nanoparticle, an active ingredient, and a phosphodiester moiety connecting the nanoparticle and the active ingredient and forms a prodrug. The nanoparticle delivery vehicle achieves the function of increasing hydrophilicity of the active ingredient and specificity against tumor cells. Advantages of the nanoparticle material include biocompatibility, magnetism and/or controllable drug release.Type: GrantFiled: July 13, 2012Date of Patent: September 30, 2014Assignee: National Cheng-Kung UniversityInventors: Jih Ru Hwu, Yu-Sern Lin, Chen-Sheng Yeh, Dar-Bin Shieh, Wu-Chou Su
-
Patent number: 8846645Abstract: The present invention relates to compounds according to general formula (I), pharmaceutical compositions comprising compounds according to general formula (I) and the use of the compounds for the treatment of a bacterial infection, particularly for use as an antibiotic.Type: GrantFiled: December 13, 2011Date of Patent: September 30, 2014Assignees: Rheinische Friedrich-Wilhelms Universität Bonn, Universität KonstanzInventors: Günter Mayer, Christina Elsbeth Luense, Valentin Wittmann, Magnus S. Schmidt
-
Patent number: 8846646Abstract: The invention relates to an unexpected discovery that propylene glycol is highly effective at killing or inhibiting Propionibacterium acnes in a mammalian skin disorder, as well as to the use of propylene glycol and salicylic acid in a skin-disorder treatment. This invention also relates to compositions containing propylene glycol alone or in combination with salicylic acid for use in killing or inhibiting Propionibacterium acnes.Type: GrantFiled: October 3, 2008Date of Patent: September 30, 2014Assignee: Winlind Skincare, LLCInventor: Win L Chiou